FIELD: medicine.
SUBSTANCE: present invention refers to immunology. What is presented is using Blinatumomab (MT103) for preparing a pharmaceutical composition for treating, relieving or eliminating acute lymphoblastic leukaemia (ALL), wherein Blinatumomab (MT103) transforms a MRD (minimal residual disease) positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL.
EFFECT: using the invention provides transforming the MRD-positive acute lymphoblastic leukaemia ALL into the MRD-negative condition of ALL molecularly that can find application in medicine in the therapy of recurrent ALL.
21 cl, 8 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW TREATMENT OF THE ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN | 2014 |
|
RU2677324C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN | 2009 |
|
RU2536933C2 |
| NEW TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN | 2018 |
|
RU2736802C2 |
| METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DOSES OF ALLOGENEIC T-CELLS WITH CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2776322C2 |
| METHODS FOR IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH 4-1BB AGONIST | 2019 |
|
RU2788524C2 |
| DOSE SCHEDULE FOR ADMINISTERING CD19×CD3 BISPECIFIC ANTIBODY | 2010 |
|
RU2548746C2 |
| COMBINATION THERAPY WITH ANTI-CD19 ANTIBODY AND A PURINE ANALOG | 2012 |
|
RU2664462C9 |
| COMBINATION THERAPY FOR STABLE AND LONG-TERM TRANSPLANT ENGRAFTMENT | 2012 |
|
RU2657758C2 |
| CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR THYMIC STROMAL LYMPHOPOIETIN RECEPTOR, AND METHODS FOR USE THEREOF | 2014 |
|
RU2701346C1 |
| BISPECIFIC ANTIBODIES AGAINST CD3*CD19 | 2015 |
|
RU2651776C2 |
